| Nov 11 |
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
|
| Oct 23 |
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
|
| Oct 7 |
MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago
|
| Sep 9 |
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
|
| Sep 3 |
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
|
| Aug 27 |
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
|
| Jun 20 |
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
|
| Jun 5 |
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
|
| Jun 4 |
MNOV: Multiple Abstracts Presented at 92nd EAS Congress…
|
| Jun 3 |
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
|
